Page 11234..10..»

Archive for the ‘Hypogonadism’ Category

Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 – Taiwan News

An extensive research report on the Hormone Replacement Therapy Market envisaged diligently by MarketResearch.Biz comprises a 360-degree view of the present market situation as well as its future growth survey. This report will offer you all the accurate data related to the different market bifurcations covering a crystal-clear idea on the Hormone Replacement Therapy market. In addition, we are literally promising you to give the perfect information on the distinct marketing angles and status over the upcoming duration of 2021-2030. There are some of the most important marketing aspects that are adequately boosting the growth of the worldwide market. They are gross margins, market penetrations, CAGR study, Porters 5 Force Model, descriptive and well-defined graphical representations, business strategies, etc.

A report comprising market current and future trends, market analyst opinions and perspectives, competitive scenario, and key regions from both regional and global aspects. This Global Hormone Replacement Therapy Market report offers an overview of the ongoing state of the market and forecasts of future progress. SWOT study is used to calculate strong market players performance and calculating their strengths and weaknesses. The report studied different factors, covering driving factors and challenges. Among its other features is the recognition of key players in the market and split study and forecasting. In addition to Hormone Replacement Therapy market new entrants, the study report helps them to estimates the market opportunity. Furthermore, the study focuses on the current issues, technical progress, and future opportunities that will influence the market. According to a study of upcoming trends, the global Hormone Replacement Therapy Market is projected to grow in the upcoming years.

Competitive Landscape with Key players:

Abbott Laboratories, Novartis, Pfizer Inc, Mylan Laboratories, Merck and Co, Novo Nordisk, Bayer Healthcare, Eli Lilly, Genentech

Hormone Replacement Therapy Market Taxonomy

Segmentation by Product: Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy.

Segmentation by Route of Administration: Oral, Parenteral, Transdermal, Others.

Segmentation by Type of Disease: Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others.

Regional Outlook: The Hormone Replacement Therapy Market

The current study analyzes the Hormone Replacement Therapy Market thoroughly. Research is also conducted for Russia, China, the United States, Taiwan, Germany, the United Kingdom, Italy, Japan, South Korea, Canada, France, Mexico, and Southeast Asia. It is expected that North America, Europe, Asia-Pacific, Latin America, and the rest of the world have the largest prudence in the Hormone Replacement Therapy market world.

Among other things, this report calculates factors that contribute to regional growth, such as the environment, Hormone Replacement Therapy market economic progress, and social factors. In the analysis, regional production records, revenue information, and manufacturer data were studied globally. Revenue and volume projection consider regional differences.

This report offers understanding into the accompanying variables:

Understanding Business Sector Development: This research provides a far-reaching outlook of the items provided by the top influencing players in the global Hormone Replacement Therapy market.

Advancement of new items: Reports anatomize the most latest innovative turns of events, innovative business strategies, and item dispatches.

Evaluating the cutthroat scene: Comprehensive investigation of market systems, geographic introduction, and item fragments of the markets prominent players.

Advancement of new business sectors: An cumulative manual for developing business sectors. Various areas are inspected across topographies in this report.

Market Expansion: The complete overview of progress and interests in the worldwide Hormone Replacement Therapy market, like new items, undiscovered topographies, and current patterns.

Get a Sample Copy Of Hormone Replacement Therapy Market Research Report Here: https://marketresearch.biz/report/hormone-replacement-therapy-market/request-sample

Significant incorporation in the Hormone Replacement Therapy market report:

Impacts of the Covid 19 on progress status, temporarily and long haul.

A portion of the business crucial patterns.

Income, volume, and deals insights are included in this report.

Mentioned development possibilities.

Market and submarket development estimations.

Roundabout and direct deals channels: positives and negatives.

Hormone Replacement Therapy market sellers, dealers, and merchants are on the top of the list.

The labor force size and rebuild spaces of each organization are crucial subtleties.

Items and administrations are provided by the important players on the lookout.

Data from each organization in regard to its calculating model, deals volumes, net income, working interest, and a portion of the complete industry.

Itemized information on showcasing strategies, highlight the market, commercialization rates, just as other business-related information.

Table of Content

Section 1: Global Hormone Replacement Therapy Industry Outlook

Section 2: Global Economic Effect on Hormone Replacement Therapy Industry

Section 3: Global Market Competition by Industry Key Players

Section 4: Global Productions, Revenue (Value), with respect to the Regions

Section 5: Global Supplies (Production), Consumption, Export, Import, globally

Section 6: Global Productions, Revenue (Value), Current Trend, Price, Product Type

Section 7: Global Market Study, on the basis of Application

Section 8: Hormone Replacement Therapy Market Pricing Study

Section 9: Market Chain Analysis, Sourcing Strategy, and Downstream Buyers

Section 10: Business strategies and vital policies by Distributors/Suppliers/Traders

Section 11: Key Marketing Strategy Study, by Key Vendors

Section 12: Market Growth Driver Analysis and Their Impact Study

Section 13: Global Hormone Replacement Therapy Market Forecast

The rest is here:
Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News

6 Things To Look for In a Good Testosterone Booster Supplement – The Portugal News

Choosing The Right Supplement Will Help You Boost Your Testosterone With No Side Effects

The hormone which is called testosterone is produced naturally in the testicles of men and ovaries of women. For men, it plays an important role in the development of make male growth and bringing in masculine characters. As for women, it is produced in smaller amounts. During the adolescent years, this hormone is produced at its best level all the way until early adulthood. Once you reach the age of 30 and above, this natural hormone starts to drop slightly each year.

While in the younger years, these hormones help to develop facial hair, deeper voice, and overall all growth development, in the years after 30, the drop in this hormone can inhibit the quality of life. To stabilize the natural growth of this hormone, people often choose supplements that are the closest thing to steroids and are naturally safe as well. This helps them to regain muscle mass and improve bone density. It allows them to enjoy a healthy sex drive and also helps to alleviate their mood. The verbal memory and thinking ability are also enhanced with the balance of this hormone.

Before you start looking for a booster, your first step should be to get examined properly by a doctor. The natural effects of low testosterone are generally decreased muscle mass, weight gain, and other conditions. However, sometimes there can be other underlying medical conditions that could be having the same symptoms. If your doctor does indeed state after the tests that you have low levels of t-hormones or hypogonadism, then you can proceed towards purchasing a supplement for the same.

A t-hormone or testosterone hormone booster can help you to benefit in many ways. However, the most crucial part of it is to buy the right one that does not cause any negative side effects. Most people prefer to buy it online as it saves them both time and money. To make sure you buy the right one you must do your due research. This will ensure that you have bought the right supplement and the ingredients are of good quality. Below are 6 things to look for when buying the testosterone booster.

When it comes to buying such supplements, there are a galore of products to choose from. This can be confusing. When you want to have the best over-the-counter testosterone booster, start by ensuring that the seller and manufacturer are indeed legitimate. This ensures that the product that you receive is of superior quality and will benefit you from its use. Research a bit on the company to see if they have been long enough in the market so that their brand is well known. Most of these drugs have a shelf life of 5 years, so if the company has been around that long as well, then it is legit. Another way to see if the company is genuine, check if they have a money-back guarantee. This claim can only be made by companies that are confident about their product so that they will not sell any low-quality ingredients. Furthermore, if the supplement does not work for you, you will get a refund.

When you are looking to buy supplements, you will need to give a closer look at all the ingredients present in them. These should be more on the natural side and of high quality. With the right ingredients and quality, you will be able to get faster and better muscle recovery. There are many ingredients that you can cross-check to see if they are scientifically proven to boost testosterone levels. These ingredients generally are fenugreek, ginseng, zinc, Vitamin D3, and so on.

When buying a booster online or from a shop, you need to ensure that the dosage is right for you. Sometimes taking a higher dosage can have more effective results but at the same time can bring in higher risks of getting the side effects. So make sure the dosage is right before investing in a supplement. You can take medical advice or that of your gym instructor to help you understand what dosage is right for you.

Reviews are helpful for all sorts of purchases of goods or services. It allows you to understand how other people with similar problems like yours, felt about their experience with a particular product or service. The same principle can be used when buying supplements. You can check other consumer reviews to see what the experience of other people has been and then make a decision if they will be effective for you as well. Of course, boosters with more positive reviews are the ones that you should go for.

While reading the positive reviews is a good idea, if there are any negative testimonials, then you should read that too. If there are quite a few negative testimonies then it will be better to refrain from the supplement. This way you will not spend your hard-earned money on something that does not seem to work.

Firstly, you should look for supplements that have no side effects but there are chances that while buying one, you will end up taking one that has some potential side effects. This could be because there would be some harmful ingredients that can have negative side effects so check it properly before use. Also, check with your doctor what are the expected side effects that you can expect so that you are more prepared.

The above points must be kept in mind when you want to find the right product. A reputable seller who is offering the products at competitive prices and has good reviews to show should be your first choice. Compare a few supplements against each other and look for something that has the best potency. Simultaneously, you can also try some natural ways by eating the right food vitamins, and herbs to help you improve your testosterone level. After all, when it comes to your health, you want to put your best foot forward.

Go here to read the rest:
6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer – DocWire News

This article was originally published here

Curr Oncol. 2021 Aug 28;28(5):3331-3346. doi: 10.3390/curroncol28050289.

ABSTRACT

Androgen deprivation therapy (ADT) is successfully used in patients with advanced prostatic cancer, but there are many concerns about its systemic side effects, especially due to advanced age and frequent comorbidities in most patients. In patients treated with ADT there are metabolic changes involving the glycaemic control and lipid metabolism, increased thrombotic risk, an increased risk of myocardial infarction, severe arrhythmia and sudden cardiac death. Still, these adverse effects can be also due to the subsequent hypogonadism. Men with heart failure or coronary artery disease have a lower level of serum testosterone than normal men of the same age, and hypogonadism is related to higher cardiovascular mortality. Many clinical studies compared the cardiovascular effects of hypogonadism post orchiectomy or radiotherapy with those of ADT but their results are controversial. However, current data suggest that more intensive treatment of cardiovascular risk factors and closer cardiological follow-up of older patients under ADT might be beneficial. Our paper is a narrative review of the literature data in this field.

PMID:34590590 | DOI:10.3390/curroncol28050289

See the rest here:
Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News

[PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell – UNLV The Rebel Yell

One of the key factors fueling the growth of the global hormone replacement therapy market is increasing acquisitions. Pfizer Inc., a pharmaceutical firm headquartered in the United States, combined with OPKO Health Inc., a business based in the U.S., in 2014 to create a long-acting growth hormone (hGH-CTP) and novel therapies for growth hormone deficient individuals. hGH-CTP is more convenient since patients just require one injection each week instead of daily dosages. In the U.S. and Europe, hGH-CTP has been designated as an orphan medication for children and adults with growth hormone deficiencies.

The expansion of the global hormone replacement therapy market is projected to be aided by a strong pipeline. In 2017, Novo Nordisk A/S, a Danish firm, completed phase 3 clinical studies for Somapacitan. This medication is used to treat adult testosterone deficiency.

FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/2079

*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report.Research Methodologyadopted for it.

Major Company Profiles Covered in This Report:Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

The market for hormone replacement treatment is projected to expand due to the rising prevalence of various chronic diseases.

The market for hormone replacement treatment is projected to expand due to the rising prevalence of hypogonadism in adult males throughout the world. Hypogonadism affects 2.1 percent to 12.8 percent of middle-aged men, according to the European Association of Urologys 2016 study. In Europe, the prevalence of low testosterone and hypogonadism symptoms in males aged 40 to 79 ranges from 2.1 percent to 5.7 percent.

The expansion of the global hormone replacement therapy market is projected to be aided by easier access and government assistance for research and development efforts. NGOs such as the National Gaucher Society provide financial assistance to patients who require expensive insulin replacement treatment.

Request Free research report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/2079

Companies are concentrating their efforts on creating generic versions of numerous medications for the treatment of diseases that are more common in women, such as hypothyroidism. On July 24, 2017, Teva Pharmaceutical Industries Ltd. introduced a generic version of Vagifem, 10 mcg, in the United States. Estradiol vaginal inserts are a kind of oestrogen used to treat atrophic vaginitis caused by menopause.

Furthermore, Mylan N.V. received FDA clearance for its Abbreviated New Medication Application (ANDA) for Estradiol Vaginal Cream USP, 0.01 percent on December 29, 2017, and therefore marketed the drug in the U.S. This cream is the first generic alternative to Allergans Estrace Cream, which is used to treat vulvar and vaginal atrophy.

Mylan is one of the few firms that sells Estradiol in cream, gel, transdermal patch, and tablet form. This will benefit both healthcare personnel and patients, as well as ensuring the businesss long-term viability.

Major companies contributing in the global hormone replacement therapy market are Pfizer Inc., QuatRx Pharmaceuticals, Mylan N.V., Abbott Laboratories, Amgen, Inc., Novartis AG, Eli Lilly and Company, Bayer AG, Merck KgaA, Teva Pharmaceutical Industries Ltd., and Novo Nordisk A/S.

Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2079

Some Notable Offerings by Coherent Market Insights Report on Hormone Replacement Therapy market:

We will provide you an analysis of the extent to which this Hormone Replacement Therapy market research report acquires commercial characteristics along with examples or instances of information that helps you to understand it better.

We will also help to identify customary/ standard terms and conditions, as offers, worthiness, warranty, and others.

Also, this report will help you to identify any trends to forecast growth rates.

The analyzed report will forecast the general tendency for supply and demand.

Also, Research Report Examines:

Competitive companies and manufacturers in global market

By Product Type, Applications & Growth Factors

Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Follow this link:
[PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell

Top 6 Benefits of Testosterone Therapy Times Square Chronicles – Times Square Chronicles

Testosterone is an essential hormone for male growth and masculine characteristics. In males, testosterone is primarily produced in testicles, and in females, it is produced in ovaries and adrenaline glands. In women, testosterone is produced in a very small amount. At adolescence, testosterone level may increase up to 30 times and after adulthood, the level decreases by a certain amount each year. In this article, we will discuss how testosterone therapy can help you by increasing your testosterone levels.

Healthy Heart and Blood Circulation

Low testosterone levels are associated with many cardiovascular risks. Testosterone helps in producing red blood cells from bone marrow. It also helps in keeping your heart healthy, ensuring a healthy blood flow to all organs and muscles of the body helping to keep the body at its peak level. A 2000s study report says that men having heart diseases after undergoing hormone therapy showed improvements in their heath. According to the U.S. Department of Veterans Affairs,in 2015 more than 83K men who underwent hormone therapy, showed a significantly lower risk of heart attack and stroke compared to untreated men.

Reduces Fat

Testosterone helps in reducing body fat and increasing muscle mass. A proper muscle mass helps in controlling the weight and increases the energy production inside the body. After getting testosterone therapy, men who had low testosterone levels previously reported a significant change in body mass and increase in strength. For better results, one must try strength enhancement exercise after therapy.

For testosterone therapy and hormone replacementvisit NovaGenix.

Strengthens Your Bones

Strong bones play an important role in supporting your bodys muscles and organs. As age increases, testosterone decreases as a result of which bone density also decreases significantly. Weak bones and osteoporosis are some common problems that men develop with age. High doses increase bone density but there is no medical evidence yet to show that an increase in testosterone levels can reduce the risks of bone fractures.

Improves Verbal Memory and Reasoning Ability

There is a strong connection between testosterone levels and thinking and verbal ability. Testosterone therapy in men of age group between 34 and 70 years showed a significant improvement in spatial memory. Men with increased testosterone levels also have a lower risk of having Alzheimers disease.

Improves Libido

Testosterone level rises naturally in response to sexual activity and arousal. Men with improved testosterone levels have higher sexual activity. It should also be noted that erectile dysfunctions are not always related to low testosterone levels, it may happen due to other conditions also.

Better Mood

Low testosterone level is often responsible for the low quality of life. Low testosterone levels cause depression, irritability, fatigue, etc. These symptoms are more common in men suffering from hypogonadism. But for men whose testosterone level decreases normally with age do not show all such mood-related symptoms.

These are the 6 benefits you can have by increasing testosterone level with testosterone therapy. Besides all these benefits, there are also some risks that you should not ignore, like increased urination, low sperm count, decrease in size of testicles, increased aggressiveness, etc.

Read the original here:
Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles

Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current…

Hormone Replacement Therapy Market Outlook 2021

Hormone Replacement Therapy market report is the major research for those who look for an entire analysis of markets. The report covers all information on the Global and regional markets, including old and future trends for market demand, size, trading, supply, competitors, prices, and globalpredominant vendors information. We have provided CAGR, value, volume, sales, production, revenue, and other estimations for the global as well as regional markets.

The market is designed to serve as a ready-to-use guide for developing accurate pandemic management programs allowing market players to successfully emerge from the crisis and retract numerous gains and profits. The SMI analyzes recent strategic activities, such as partnerships, acquisitions, mergers, collaborations, and joint ventures. The report analyzes the demographics, growth potential, and capability of the market through the forecast period 2021 to 2027. The players included in this report are chosen in terms of their product portfolio, market share, brand value, and the well-being of the organizations. Our report is based on current situations across the globe.

You can get a sample copy of the report here @ https://www.stratagemmarketinsights.com/sample/13322

Top players listed in Hormone Replacement Therapy report:

Novartis AG, Abbott Laboratories, Mylan NV, Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen Inc., Eli Lilly and Company

Hormone Replacement Therapy Market Segmentation

Global Hormone Replacement Therapy Market,By Type

Oral, Parenteral, Others

Global Hormone Replacement Therapy Market,By Applications:

Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Others

If you are part of the Hormone Replacement Therapy industry or intend to be, then study would provide you comprehensive outlook. It is vital to keep your market knowledge up to date analysed by major players and high growth emerging players. If a different set of players need to be analysed as per geography or regional target then enquire us with your customized requirements.

The report forecasts revenue growth at all geographic levels and provides an in-depth analysis of the latest industry trends and development patterns from 2020 to 2027 in each of the segments and sub-segments.

To Access and buy a Complete Report @ https://www.stratagemmarketinsights.com/cart/13322

Available Customizations:

This report also offers specific consumer preferences and expectations to gain insights into changing needs and behavior of the consumer. Thus, we offer more reliable, accurate, and actionable information specifically tailored to suit your business needs. If you have any special requirements, please let us know and we will offer you the report as you want.

Some of the important Key Questions ones are:

Research Methodology:

TheHormone Replacement Therapy market research follows a four-step methodology: primary research, secondary research, market estimation, and final presentations. Data is collected through self-conducted research methods in the primary research, whereas in secondary research, data is collected from previously conducted studies.The market estimation involves data processed in primary and secondary research. The final step is a holistic representation of the data and analysis made to make the report highly comprehensible for the reader.

Get Premium Discount on this Report @ https://www.stratagemmarketinsights.com/discount/13322

**NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers to post the COVID-19 crisis.

Why Opt for Stratagem Market Insights Reports?

Our strength lies in the unrivaled diversity of our people, methodologies, specialisms, and points of view. This market has a significant impact on the COVID-19 pandemic. Our experts are closely monitoring the industry to capture and analyze appropriate indicators.

Explore ByMN

Here is the original post:
Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current...

9 Ways to Increase Testosterone Naturally in 2021 – Men’s Journal

What makes a man? This question has been a subject of great argument for many centuries. However, the thing that leaps to the mind first is, undeniably, testosterone. Testosterone is the most vital male sex hormone that is a critical factor in mens adolescence.

An optimal proportion of testosterone maintains high energy levels as well as enhances body strength and masculinity. Besides, it is a crucial aspect regarding physical changes in boys.

But, what course of action should you adopt if you have lower testosterone levels? You will find a vast chain of treatments and procedures in this regard, but it is hard to access an authentic one.

In that sense, you have landed on the right platform. With enough research on this significant health affair, we will introduce you to the precious nine ways that will help you increase testosterone naturally. And, the good news is these will bring beneficial changes to your overall health and well-being.

So, keep scrolling down.

Your diet has a significant impact on your testosterone levels. Recent studies have found that men who consume a low-fat diet face testosterone deficiency. Therefore, always be mindful of your diet routine and stay away from prolonged dieting strategies.

Eating bulked-up ingredients fuels your masculinity. Therefore, following a rich diet plan and the intake of the best testosterone booster supplements might boost up your testosterone levels effectively.

You might be missing some essential nutrients in your daily diet that may boost your T levels.

We have discussed their importance and how you can have all of them at once below in detail:

D-Aspartic acid is a natural amino acid that can increase your testosterone levels effectively. Colossal research has been done on D-Aspartic acid, which shows it is bound to many fruitful outcomes regarding the whole male reproductive system.

Recent studies have revealed D-Aspartic acid works on some critical testosterone-stimulating hormones like follicle-stimulating hormones and luteinizing hormones, which increases your testosterone levels.

Adding D-Aspartic acid into your diet for 12 days may help enhance testosterone levels and other hormones. Additionally, it may also elevate their production and transportation around the body.

Many studies have also shown that such amino acids may be helpful in sperm production and quality. So, overall, it can be a significant step towards better testosterone levels.

Magnesium is a critical mineral deeply associated with the vital processes in our body, like cellular processes, bone formation, and muscle functions.

A couple of researches revealed magnesium supplementation for four weeks increases testosterone levels in athletic and sedentary individuals.

A magnesium-rich diet can, directly and indirectly, translate it into an increased T level (since magnesium is also responsible for converting Vitamin D into an active form).

Although magnesium deficiency is more common in old age, many younger people, like athletes, may also suffer from it, as many minerals like Zinc, magnesium, etc., may be lost in sweat. Therefore, make sure you consume a proper intake of magnesium.

Though many competitive supplements include magnesium as an ingredient, dietary magnesium always comes first, so try to reach out to the magnesium-rich foods that are abundant, such as greens, nuts, seeds, dry beans, whole grains, and wheat and oat bran.

Try to stay away from magnesium oxide, as it may cause some significant health issues like intestinal discomfort or diarrhea.

Zinc is found to be the second most abundant element in humans. Apart from having countless benefits in other health regards, researchers have found Zinc may play a tremendous role in mens masculinity, fertilization, sperm quality, and hormonal secretion.

Some researchers have also witnessed that an average Zinc concentration in the body is required for the normal functioning of the pituitary gland, which is highlighted in male reproductive potential.

Zinc is found to affect mens fertility in numerous ways. In addition, low zinc levels in the body have a highlighted negative effect on testosterone concentrations.

So, keeping all of this in mind, try to incorporate zinc supplements in your diet, which include oysters, beef, nuts, chicken, beans, and many more.

TestoPrime is the answer, as it is an effective testosterone-boosting supplement. With TestoPrime, you can get all of the essential nutrients in a single package.

You can get all of these benefits by using this natural testosterone booster. The influential testosterone support can help you maintain your pubescent liveliness with new and fresh testosterone.

TestoPrime is a cost-friendly and 100% dependent combination of natural ingredients, like vitamins and fruit extracts, mainly created to give the best results and promote your overall health.

Men who have entered their 40s or are near to it are advised to purchase it. It may not only bring a flood of testosterone into your body, but it may also help you get rid of tiredness, low energy levels, loss of focus, decreased sexual desires, and a bad memory.

So, if you want all these in a short time, grab this fantastic T-boosting supplement.

Modern studies have shown testosterone makes you manly, and vitamin D supports your bones and muscles. However, recently, it has been concluded these two biomarkers are associated with many other body functions and may affect each others levels.

Vitamin D is an essential nutrient that is achieved via sun exposure and many diet supplements. The essential vitamin crucially influences the proper growth and functioning of bones, muscles, nerves, and numerous body organs.

Various researches have been performed on discovering the role of vitamin D in testosterone boosting. It has been found that low vitamin D levels can drop your testosterone levels theoretically. Additionally, it can lead to improper working of the testes.

A few years ago, it was concluded that men with lower Vitamin D and T levels might have more cardiovascular diseases. In addition, people with low T levels may experience some other sexual problems like erectile dysfunction and lower sexual drives. These can be treated with Vitamin D.

Always make sure to have enough Vitamin D included in your diet. There are various supplements available in the market. Another option is to go out in the sunshine, as it is the most reliable and productive way of consuming vitamin D.

Therefore, the sun is the best way to get vitamin D. When you take some Vitamin D-rich supplements or expose your skin to sun rays, your body absorbs it. Your liver will then translate it into its active form called 25(OH) D, which your doctor looks for when he suggests a Vitamin D blood test.

The active form of Vitamin D is then transported throughout your body for different functions. It is now proven the male reproductive system is one of its receivers.

Apart from that, there are some other ways to consume vitamin D like:

Exercises tend to be the most crucial factor in preventing many health diseases. Surprisingly, this can also be the best alternative to increase your testosterone levels. You can increase your testosterone levels on your own by adopting some essential pieces of training and workouts.

Low testosterone levels are nearly bound to lowered energy levels, decreased muscle mass, and inadequate mental health. Exercises can be the best in this regard.

Exercises increase testosterone in two ways:

Research has found that heavy training like weight lifting may be the best way to boost testosterone. Lifting heavy weights may help gain muscle mass and, likewise, higher T levels. If you are new to this, opt for a trainer to get basic knowhow of it.

High-intensity interval exercises, if done along with weight lifting, may be the best combination that will not only elevate your T levels but may also help promote heart health.

High-intensity training is also found to have positive effects on testosterone levels. Research revealed that resting for a couple of minutes between intervals is more advantageous.

Moderate cardio exercises also contribute to some extent, as they protect your heart and inhibit extra cortisol productions, which can negatively impact your muscle mass and T levels.

Make sure to stay away from chronic and prolonged exercises like cycling, running, and swimming for a long time, as these may cause problems regarding your testosterone production.

Follow a reliable diet plan that includes the intake of all of the necessary nutrients in the proper proportions. A balanced diet is a crucial factor in elevating T levels. Hundreds of researches show that low testosterone levels and poor diet patterns are strongly interrelated.

A balanced diet not only enhances your T levels, but it has countless health benefits. Many studies show that alterations in dietary plans may lead to hypogonadism. Consuming a balanced diet enriched in proteins, carbs, and healthy fats can go longer toward normal T levels as you age.

Many essential nutrients like proteins, carbs, and healthy fats may bring noticeable benefits to your health and hormonal secretions.

According to recent health researchers, a diet rich in proteins may aid a lot in testosterone boosting. However, another study has revealed low protein levels may damage the Leyden cells assigned to testosterone production.

Therefore, try to increase your protein intake. This will help you in fat loss which, likewise, is linked with your testosterone. Moreover, it will support your muscle development, which may be essential in testosterone boosting.

Carbs may bring out a rapid increase in your T levels. According to the latest research, eating a carbohydrate-rich diet may be harmful to diabetic people, but it is associated with a high testosterone level in the average person. Instead, try to consume carbs from starchy tubers such as potatoes, yams, pumpkins, etc.

When it comes to fats, many of you may think it has nothing to do with testosterone levels, but it is essential to take a sufficient amount of healthy fats to produce testosterone effectively. In this regard, saturated fats are beneficial.

It would be best if you add the following foods to your daily routine:

In short, we would say a healthier diet will result in a healthier weight that may boost your T levels even if you age.

The pressures you are dealing with in your life may reveal several ways. Lower T levels are one of these. Stress may affect some essential hormones like testosterone responsible for pubescence in boys. However, the clear physiological linkage between stress and low testosterone is not known.

Many researchers and physicians have shown some brain chemicals released in response to stress and anxiety, and then they might be transferred to the testosterone-controlling sites in the brain.

Other research shows stress elevates the cortisol levels in the body. Cortisol is a stress hormone released by adrenal glands in the kidneys when you are under stress. It is assigned with the management of numerous processes in the body like metabolism and immune system. Therefore, increased cortisol impacts testosterone productions negatively.

In this regard, meditation may be the best option to get rid of stress. Researchers have found that at least 20-30 minutes of meditation per day will indirectly lower cortisol and increase your testosterone and growth hormone levels.

Always try to manage yourself in stressful situations. This will preserve your sanity and promote your health in many ways.

Lack of sleep can adversely affect the secretions and levels of many essential hormones and chemicals in the body, including testosterone. Simply speaking, your testosterone levels are directly linked with your sleep. So, the longer you sleep, the higher your T levels will be.

Recent studies have disclosed that testosterone production is at its peak during the REM stage of your sleep. Many physicians also suggest that for a healthy testosterone level, around seven to nine hours of sleep are required.

People who have problems regarding their sleep should consult a doctor, as they unconsciously face a significant problem.

Your T levels are also affected by many other factors. For example, healthier life is based upon the regulation of your sex hormones like testosterone.

Always try to stay away from some chemicals like endocrine disruptors, as they can spoil your hormones badly. Some of them are estrogens compounds that can adversely affect your T levels. So, try to maintain a distance from BPA, Parabens, and other chemicals.

They act as estrogen-rich elements, and your body may make mistakes in recognizing them due to their similar composition. They create disturbances in normal body functions. So, choose the products which do not have them.

It is a common fact that excessive alcohol and drug consumption may have several adverse effects on your health and, particularly, on your liver. But, does alcohol affect your T levels?

The answer is yes. When you consume alcohol and other similar drugs, your body requires a lot of time to break and process the alcohol. In this way, your system focuses mainly on this task ,which in turn, causes your liver to work more.

During this process, your liver does not get time to perform its other functions, like breaking down some hormones, including estrogen and testosterone. In other words, when you consume alcohol regularly, your testosterone levels are not the same as they are when you avoid alcohol.

Some men are still having a proper T level while consuming alcohol, but that is rare. If you want a normal and healthy T level, it should be your top concern to avoid alcohol and other drug supplements.

Even in just 30 days, you can get an average level of testosterone after quitting your alcohol and drug consumption. Proper T levels are an essential part of your health and well-being. Therefore, staying away from alcohol and drug consumption can be the easiest step to achieve such goals.

Mental health is something that should never be ignored. Talking about how it affects testosterone levels in the body, you might not believe us. But, if you are stressed out and mentally upset, your T-levels drop significantly low.

Do not hesitate to consult a psychiatrist whenever you feel like there is something troubling you and making you depressed. Always talk about your mental health with professionals, as it is not a thing to be ignored.

More to keep in mind is to constantly check the medications you are taking for other health problems. This is because they might contain any ingredient that promotes low T levels. This might not happen, but you should be careful and talk to your online therapist if you feel anything like that.

Testosterone is an important male sex hormone that promotes masculinity. It also facilitates many other body functions.

A lot of options are available in the market to boost your T levels, including many therapies, treatments, artificial supplements, and pills. But, the best way to do so is to follow or implement something natural.

In addition to following the simple tips we mentioned above, TestoPrime might help you a lot with getting your testosterone levels boosted up. It is associated with many extra health benefits regarding your heart, brain, and weight balance in addition to boosting T-levels.

However, if you are already on some kind of medication, or have a particular medical condition, make sure to consult your doctor before opting for any supplement.

For access to exclusive gear videos, celebrity interviews, and more, subscribe on YouTube!

More:
9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal

Testosterone Therapy for Hypogonadism Guideline Resources …

Full Guideline: Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice GuidelineJCEM | March 2018

Shalender Bhasin, Juan P. Brito, Glenn R. Cunningham, Frances J. Hayes, Howard N. Hodis, Alvin M. Matsumoto, Peter J. Snyder, Ronald S. Swerdloff, Frederick C. Wu, Maria A. Yialamas

Differences between the 2010 and 2018 guidelines:

+1.0 Diagnosis of Hypogonadism in Men

1.1 We recommend diagnosing hypogonadism in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum total testosterone and/or free testosteroneconcentrations (when indicated). (1 |O)

1.2 We recommend against routine screening of men in the general population for hypogonadism. (1 |OO)

1.3 In men who have hypogonadism, we recommend distinguishing between primary (testicular) and secondary (pituitaryhypothalamic) hypogonadism by measuring serum luteinizing hormone and follicle stimulating hormone concentrations. (1 |O)

1.4 In men with hypogonadism, we suggest further evaluation to identify the etiology of hypothalamic, pituitary, and/or testicular dysfunction. (2 |OO)

+2.0 Treatment of Hypogonadism with Testosterone

2.1 We recommend testosterone therapy in hypogonadal men to induce and maintain secondarysex characteristics and correct symptoms of testosterone deficiency. (1 |O)

2.2. We recommend against testosterone therapy in men planning fertility in the near term or in men with breast or prostate cancer, a palpable prostate nodule or induration, a prostate-specific antigen level >4 ng/mL, a prostate-specific antigen level >3 ng/mL combined with a high risk of prostate cancer(without further urological evaluation), elevated hematocrit, untreated severe obstructive sleep apnea,severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke withinthe last 6 months, or thrombophilia. (1 |OO)

2.3 In hypogonadal men 55 to 69 years old, who are being considered for testosterone therapy andhave a life expectancy >10 years, we suggest discussing the potential benefits and risks of evaluatingprostate cancer risk and prostate monitoring and engaging the patient in shared decision makingregarding prostate cancer monitoring. For patients who choose monitoring, clinicians should assessprostate cancer risk before starting testosterone treatment and 3 to 12 months after starting testosterone. (2 |OOO) In hypogonadal men being considered for testosterone therapy who are 40 to69 years old and at increased risk of prostate cancer (e.g., African Americans and men with a first-degreerelative with diagnosed prostate cancer), we suggest discussing prostate cancer risk with the patient andoffering monitoring options. (2 |OOO)

2.4 We suggest against routinely prescribing testosterone therapy to all men 65 years or older withlow testosterone concentrations (1 |OO). In men.65 years who have symptoms or conditionssuggestive of testosterone deficiency (such as low libido or unexplained anemia) and consistentlyand unequivocally low morning testosterone concentrations, we suggest that clinicians offertestosterone therapy on an individualized basis after explicit discussion of the potential risks andbenefits. (2 |OO)

2.5 We suggest that clinicians consider short-term testosterone therapy in HIV-infected men with low testosterone concentrations and weight loss (when other causes of weight loss have been excluded)to induce and maintain body weight and lean mass gain. (2 |OO)

2.6 In men with type 2 diabetes mellitus who have low testosterone concentrations, we recommendagainst testosterone therapy as a means of improving glycemic control. (1 |OO)

+3.0 Monitoring of Testosterone Replacement Therapy

3.1 In hypogonadal men who have started testosterone therapy, we recommend evaluating the patient after treatment initiation to assess whether the patient has responded to treatment, is suffering any adverse effects, and is complying with the treatment regimen. (Ungraded Good Practice Statement)

3.2 We recommend a urological consultation for hypogonadal men receiving testosterone treatmentif during the first 12 months of testosterone treatment there is a confirmed increase in prostate specificantigen concentration >1.4 ng/mL above baseline, a confirmed prostate-specific antigen >4.0 ng/mL, or a prostatic abnormality detected on digital rectal examination. After 1 year, prostate monitoring should conform to standard guidelines for prostate cancer screening based on the race and age of the patient. (2 |OO)

Read the rest here:
Testosterone Therapy for Hypogonadism Guideline Resources ...

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And…

If approved, CLAR-121 would be the first T treatment of its kind for inflammatory breast disease.

HavaH has extensive clinical experience with CLAR-121 in more than 1,000 Australian women (more than 6,200 implants) with breast disease, and Clarus expects that access to HavaH's pharmacokinetics, safety and early efficacy data in PDM will expedite progression to Phase 2/3 clinical studies in the U.S. Clarus estimates that the annual U.S. market size for PDM exceeds $400 million.2,3,4With this new pipeline asset, Clarus may also pursue, alone or in partnership, future indications in ER+ breast cancer, macromastia, granulomatous mastitis, and autoimmune induced breast pain.

"This licensing agreement marks the beginning of an exciting new partnership with HavaH. Their experience coupled with the significant amount of clinical data generated in Australia will benefit Clarus greatly as we begin our development activities in the U.S.," said Dr. Robert Dudley, Clarus's founder, president and CEO. "CLAR-121 allows us to leverage our expertise in androgen biology, as exemplified by JATENZO, a testosterone replacement therapy (TRT) for male hypogonadism and Clarus's first commercial product, and expands our development pipelinewith an initial focus on PDM in women a debilitating, painful disease with very limited treatment options, short of invasive surgery. This treatment, if approved, has the potential to be life-changing for women who suffer from PDM, and its development fits well with our mantra: 'good is never good enough'. Our goal is to provide treatment options that not only produce a positive clinical outcome, but also provide a positive therapeutic experience for patients."

Under the terms of the licensing agreement, Clarus will be responsible for future global development and regulatory activities for CLAR-121, excluding Australia. Clarus will pay HavaH an upfront payment of $500,000 upon signing and HavaH may be eligible for up to $10.75 million in potential development and regulatory milestone payments. HavaH will retain the right to promote HAVAH T+Aiin Australia. Additionally, HavaH would be eligible for a modest royalty and up to $30 million in potential commercial milestones.

"We developed HAVAH T+Ai to address a significant unmet need in women's health, and our partnership with Clarus will enable us to advance this therapeutic approach not only for inflammatory breast disease but, more widely we hope, for ER+ breast cancer where data now unambiguously demonstrates that the androgen receptor has an important tumor suppressor role in this form of breast cancer,"5 said Stephen Birrell, MD, PhD, HavaH founder, chairman and chief medical officer.

"In Clarus, we found a partner who understands and appreciates the potentially profound importance of androgen action in the context of inflammatory breast disease, as well as its role as an adjunctive endocrine therapy for certain forms of breast cancer," said Kathy Harrison, HavaH CEO.

Reedland Capital Partners, acting through Weild & Co., member FINRA/SIPC, served as financial advisor to HavaH in connection with this transaction. For more information, please visit http://www.reedland.com.

About Clarus Therapeutics, Inc.

Clarus is a pharmaceutical company with expertise and interest in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications.Clarus successfully developed and brought to market JATENZO (testosterone undecanoate oral capsules; CIII) a new state-of-the-art oral TRT. JATENZO was launched in February 2020 as the first and only FDA-approved oral softgel for TRT in adult males who have low or no testosterone due to certain medical conditions.6,7,8For more information, visit http://www.clarustherapeutics.com and http://www.JATENZO.com.

At the end of April, Clarus announced a new chapter for the company as it entered into a definitive business combination agreement with Blue Water Acquisition Corp. (NASDAQ: BLUW), a special purpose acquisition company (SPAC), that will result in Clarus becoming a publicly traded company when the transaction closes in the third quarter of 2021.

About HavaH Therapeutics

HavaH Therapeutics is an Australia-based women's hormonal health biopharmaceutical company founded in 2005. HavaH's transition into the U.S. market was facilitated by the appointment in 2017 of San Francisco-based Executive Director Ronald Martell.

HavaH is developing innovative, proprietary hormonal therapies that aim to improve quality of life for women across the world. HavaH brings together a world-class team passionate about helping women live lives free from the suffering caused by breast pain, debilitating menopausal symptoms and breast cancer. More information is available at http://www.havahtx.com

Clarus Forward-Looking Statement

Certain statements in this press release and the information incorporated herein by reference may constitute "forward-looking statements" for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the success, cost and timing of our product development activities and clinical trials, including our estimates regarding timing to commence future clinical trials, the potential attributes and benefits of our product candidates, the potential attributes and benefits of product candidates, including CLAR-121, our ability to obtain and maintain regulatory approval for our product candidates and our ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the preliminary proxy/prospectus for our proposed business combination, and those that are included in any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the COVID-19 pandemic and there may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

About JATENZO

Indication

JATENZO (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Limitation of use

Safety and efficacy of JATENZO in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASES IN BLOOD PRESSURE

CONTRAINDICATIONS

JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

WARNINGS AND PRECAUTIONS

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence 2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure. You can also obtain information regarding JATENZO at http://www.jatenzo.com.

1 Zhang, Yanna et al. Clinical characteristics, classification, and surgical treatment of periductal mastitis. J Thorac Dis 2018; 10(4): 2420-2427.

2 Dixon JM, et al. Periductal mastitis and duct ectasia: different conditions with different aetiologies. Br J Surg 1996; 83: 820-822.

3 Eberl MM, Phillips RL, Jr., Lamberts, H, et al. Characterizing breast symptoms in family practice. Ann Fam Med 2008; 6(6):528-33.

4 US Census Bureau, accessed on 06/15/2020: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2018_SHS_Table_A-18.pdf.

5 Hickey, TE, Selth, LA, Chia, KM, et al. The androgen receptor is a tumor suppressor in estrogen receptor positive breast cancer. Nat. Med. 2021; 27: 310-320.

6 JATENZO (testosterone undecanoate) [prescribing information]. Clarus Therapeutics, Inc.

7 US Food & Drug Administration. FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206089. Accessed October 1, 2019.

8 US Food & Drug Administration. NDA Approval Letter. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206089Orig1s000ltr.pdf

SOURCE Clarus Therapeutics Inc.

https://clarustherapeutics.com/

Read more:
Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And...

Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer – Brockville…

InForGrowth added a new report on Male Hypogonadism Market Growth Analysis 2021-2026 provides an in-depth study on the current state of the global Industry by explicating the key development trends, limitations, challenges, and opportunities that will mold the business dynamics in the coming years. Also, the Male Hypogonadism Market report highlights the top regional markets and reveals the major areas to further business development, while providing a comprehensive account of the prominent companies in this domain. Apart from this, it also gauges the impact of the COVID-19 pandemic on revenue generation and breaks down the business strategies employed by well-established organizations to adapt to the changes in this industry.

Click Here to Get Sample Copy of Report @ https://www.inforgrowth.com/sample-request/6323584/Male Hypogonadism-market

The report covers the following key players in the Male Hypogonadism Market:

Key highlights covered in the Male Hypogonadism market report are competitive landscape, high potential prospects, and future growth visions and provide a wide range of data for helping industry players to survive in the competitive global Male Hypogonadism market. It also captures the effect of economic setup on prospects in key expansion segments. This unique market study report depicts relevant market data including new platforms, developments, and tools introduced in the Male Hypogonadism market.

Segmentation of Male Hypogonadism Market:

By the product type, the market is primarily split into

By the application, this report covers the following segments:

Male Hypogonadism Geographic Market Analysis:

This report analyzes the Male Hypogonadism market in terms of market reach and customer base in key geographic market regions. The Male Hypogonadism market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Male Hypogonadism market presence in the major regions. It defines the market share, market size, sales, distribution network, and distribution channels for each regional segment.

Get a Customization report as Per Requirements @https://www.inforgrowth.com/customization/6323584/Male Hypogonadism-market

Major Highlights from the Covid-19 Impact Analysis:

-Impact of the Covid-19 pandemic on the global economy.

-Variations in the supply & demand due to disruption of distribution channels.

-Initial as well as future impact analysis of the pandemic on business growth.

This market research report can be a great solution to help you make better decisions, earn maximum income, and improve business profits. This market research report offers a systematic idea of the current scenario of the global market. Recent developments, product launches, joint ventures, capacities, production values, mergers, and acquisitions have supported various market dynamics. Comprehensive Male Hypogonadism market research report not only offers the chance to outlast the competition but also outperform the competition.

Table of Content of Male Hypogonadism Market Report 2021-2026:Chapter 1: Male Hypogonadism Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Male Hypogonadism Market ForecastContinued

To Buy the Full Report, Connect with us athttps://www.inforgrowth.com/purchase/6323584/Male Hypogonadism-market

For More Details Contact Us:

Contact Name:Rohan

Email:[emailprotected]

Phone:1-909-329-2808

Here is the original post:
Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville...

Male menopause: Here’s everything you need to know about andropause – Pulse Ghana

If scientific studies are to be believed, men also go through hormonal changes after the age of 50. However, it is very different from what women go through.

This has been a controversial topic for several years. According to a study, male menopause is nothing like female menopause. Female menopause is a natural part of ageing for women, whereas, male menopause doesnt even affect some older men. Due to the significant differences between the two conditions, doctors prefer calling it andropause or late-onset hypogonadism.

In andropause, the production of testosterone and other hormones decline in men. Testosterone is a hormone that leads to changes during puberty, manages your physical and mental health, maintains muscle mass, fuels sex drive and other important functions in the body.

The condition is also known as testosterone deficiency and late-onset hypogonadism. It is often associated with hypogonadism, which shows similar symptoms to this condition.

Here is everything you need to know about andropause or male menopause.

As per studies, this condition can cause a variety of symptoms and complications in the body.

Not able to focus on things

Reduced bone density and muscle mass

Your doctor might take a blood sample to test your testosterone levels. However, in most cases, the symptoms are manageable without treatment. Making healthy lifestyle choices can help you alleviate the symptoms. So, eating healthy, regular exercise, adequate sleep, and less stress are some lifestyle changes that may help.

In case youre experiencing depression, your doctor may prescribe antidepressants, therapy and the above-mentioned lifestyle changes.

Read the original:
Male menopause: Here's everything you need to know about andropause - Pulse Ghana

Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory…

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

Agreement aims to accelerate development of a unique testosterone treatment for inflammatory breast diseases and estrogen-receptor positive breast cancer

NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ('Clarus'), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics ('HavaH'), an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormone/immune interface, today announced a licensing agreement whereby Clarus will acquire the exclusive worldwide (excluding Australia) development and commercialization rights for HAVAH T+Ai (CLAR-121).

If approved, CLAR-121 would be the first T treatment of its kind for inflammatory breast disease.

CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predominantly affects women. If approved, CLAR-121 would be the first T treatment of its kind for inflammatory breast disease, including inflammatory periductal mastitis (PDM) and estrogen receptor-positive (ER+) breast cancer. Clarus's initial clinical development target is PDM - a destructive autoimmune inflammatory process of the retro-areolar milk ducts that results in multiple fistulae and inevitably results in disfiguring surgery and a high risk of recurrence. There is no known treatment for this condition apart from surgery, which has significant limitations.1 Due to the low prevalence of PDM in the U.S., Clarus anticipates this disease could qualify for orphan drug designation by the U.S. Food and Drug Administration and plans to petition the agency for that status for CLAR-121.

HavaH has extensive clinical experience with CLAR-121 in more than 1,000 Australian women (more than 6,200 implants) with breast disease, and Clarus expects that access to HavaH's pharmacokinetics, safety and early efficacy data in PDM will expedite progression to Phase 2/3 clinical studies in the U.S. Clarus estimates that the annual U.S. market size for PDM exceeds $400 million.2,3,4 With this new pipeline asset, Clarus may also pursue, alone or in partnership, future indications in ER+ breast cancer, macromastia, granulomatous mastitis, and autoimmune induced breast pain.

'This licensing agreement marks the beginning of an exciting new partnership with HavaH. Their experience coupled with the significant amount of clinical data generated in Australia will benefit Clarus greatly as we begin our development activities in the U.S.,' said Dr. Robert Dudley, Clarus's founder, president and CEO. 'CLAR-121 allows us to leverage our expertise in androgen biology, as exemplified by JATENZO, a testosterone replacement therapy (TRT) for male hypogonadism and Clarus's first commercial product, and expands our development pipeline with an initial focus on PDM in women - a debilitating, painful disease with very limited treatment options, short of invasive surgery. This treatment, if approved, has the potential to be life-changing for women who suffer from PDM, and its development fits well with our mantra: 'good is never good enough'. Our goal is to provide treatment options that not only produce a positive clinical outcome, but also provide a positive therapeutic experience for patients.'

Under the terms of the licensing agreement, Clarus will be responsible for future global development and regulatory activities for CLAR-121, excluding Australia. Clarus will pay HavaH an upfront payment of $500,000 upon signing and HavaH may be eligible for up to $10.75 million in potential development and regulatory milestone payments. HavaH will retain the right to promote HAVAH T+Ai in Australia. Additionally, HavaH would be eligible for a modest royalty and up to $30 million in potential commercial milestones.

'We developed HAVAH T+Ai to address a significant unmet need in women's health, and our partnership with Clarus will enable us to advance this therapeutic approach not only for inflammatory breast disease but, more widely we hope, for ER+ breast cancer where data now unambiguously demonstrates that the androgen receptor has an important tumor suppressor role in this form of breast cancer,'5 said Stephen Birrell, MD, PhD, HavaH founder, chairman and chief medical officer.

'In Clarus, we found a partner who understands and appreciates the potentially profound importance of androgen action in the context of inflammatory breast disease, as well as its role as an adjunctive endocrine therapy for certain forms of breast cancer,' said Kathy Harrison, HavaH CEO.

Reedland Capital Partners, acting through Weild & Co., member FINRA/SIPC, served as financial advisor to HavaH in connection with this transaction. For more information, please visit http://www.reedland.com.

About Clarus Therapeutics, Inc.

Clarus is a pharmaceutical company with expertise and interest in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. Clarus successfully developed and brought to market JATENZO (testosterone undecanoate oral capsules; CIII) - a new state-of-the-art oral TRT. JATENZO was launched in February 2020 as the first and only FDA-approved oral softgel for TRT in adult males who have low or no testosterone due to certain medical conditions.6,7,8 For more information, visit http://www.clarustherapeutics.com and http://www.JATENZO.com.

At the end of April, Clarus announced a new chapter for the company as it entered into a definitive business combination agreement with Blue Water Acquisition Corp. (NASDAQ: BLUW), a special purpose acquisition company (SPAC), that will result in Clarus becoming a publicly traded company when the transaction closes in the third quarter of 2021.

About HavaH Therapeutics

HavaH Therapeutics is an Australia-based women's hormonal health biopharmaceutical company founded in 2005. HavaH's transition into the U.S. market was facilitated by the appointment in 2017 of San Francisco-based Executive Director Ronald Martell.

HavaH is developing innovative, proprietary hormonal therapies that aim to improve quality of life for women across the world. HavaH brings together a world-class team passionate about helping women live lives free from the suffering caused by breast pain, debilitating menopausal symptoms and breast cancer. More information is available at http://www.havahtx.com

Clarus Forward-Looking Statement

Certain statements in this press release and the information incorporated herein by reference may constitute 'forward-looking statements' for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the success, cost and timing of our product development activities and clinical trials, including our estimates regarding timing to commence future clinical trials, the potential attributes and benefits of our product candidates, the potential attributes and benefits of product candidates, including CLAR-121, our ability to obtain and maintain regulatory approval for our product candidates and our ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading 'Risk Factors' in the preliminary proxy/prospectus for our proposed business combination, and those that are included in any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the COVID-19 pandemic and there may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

About JATENZO

Indication

JATENZO (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Limitation of use

Safety and efficacy of JATENZO in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASES IN BLOOD PRESSURE

CONTRAINDICATIONS

JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

WARNINGS AND PRECAUTIONS

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence 2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure. You can also obtain information regarding JATENZO at http://www.jatenzo.com.

1 Zhang, Yanna et al. Clinical characteristics, classification, and surgical treatment of periductal mastitis. J Thorac Dis 2018; 10(4): 2420-2427.

2 Dixon JM, et al. Periductal mastitis and duct ectasia: different conditions with different aetiologies. Br J Surg 1996; 83: 820-822.

3 Eberl MM, Phillips RL, Jr., Lamberts, H, et al. Characterizing breast symptoms in family practice. Ann Fam Med 2008; 6(6):528-33.

4 US Census Bureau, accessed on 06/15/2020: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2018_SHS_Table_A-18.pdf.

5 Hickey, TE, Selth, LA, Chia, KM, et al. The androgen receptor is a tumor suppressor in estrogen receptor - positive breast cancer. Nat. Med. 2021; 27: 310-320.

6 JATENZO (testosterone undecanoate) [prescribing information]. Clarus Therapeutics, Inc.

7 US Food & Drug Administration. FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206089. Accessed October 1, 2019.

8 US Food & Drug Administration. NDA Approval Letter. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206089Orig1s000ltr.pdf

Disclaimer

Blue Water Acquisition Corporation published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 16:46:07 UTC.

Read the original post:
Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory...

Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current – The Manomet Current

Hormone Replacement Therapy Market is valued atUSD 21.04 Billionin 2020 and expected to reachUSD 36.54 Billionby 2027 with theCAGR of 8.20%over the forecast period.

Global Hormone Replacement Therapy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027The growing awareness on post-menopausal issues among women is one of the major factors driving the growth of Global Hormone Replacement Therapy Market.

Get Sample Report:@ https://brandessenceresearch.com/requestSample/PostId/1402

Hormone replacement therapy is a treatment used to release symptoms of the menopause. The main advantage is that it is a very effective method of controlling menopausal symptoms, and it can make an important difference to a womans quality of life and security. Hormone replacement therapy can also reduce a womans risk of developing osteoporosis and cancer of the colon and rectum. Additionally, hormones are secreted predominantly from the endocrine glands and absorbed into the bloodstream. The hormones that have been most commonly utilised in hormone replacement therapy are progesterone, estrogen, testosterone, adrenal hormones, DHEA, thyroid hormones, pregnenolone, melatonin, and human growth hormone. It is the most effective treatment for menopause symptoms. Systemic hormone replacement therapy helps in treating cancer, rheumatoid arthritis and other diseases. Moreover, this treatment is particularly favorable for patients with growth hormone deficiency, women nearing menopause and elderly people suffering from hypogonadism. It may also protect against osteoporosis.

Global Hormone Replacement Therapy market report is segmented on the basis of product, administration, disease and region & country level. Based upon product, global hormone replacement therapy market is classified into estrogen replacement therapy, human growth hormone replacement therapy, thyroid replacement therapy and testosterone replacement therapy. Based upon administration, the market is divided into oral, parenteral and transdermal. Based upon disease, global hormone replacement therapy market is classified into menopause, hypothyroidism, male hypothyroidism, growth hormone deficiency, cancer and other.

The regions covered in this Hormone Replacement Therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Hormone Replacement Therapy sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Afria, etc.

Global Hormone Replacement Therapy report covers prominent players Abbott Laboratories, Novo Nordisk, Novartis, Merck Serono, Bayer Healthcare, Eli Lilly, Mylan Laboratories, Roche, Genentech, Orion Pharma AB, Allergen Plc and others.

News-

September 12th, 2017; after a massive study of hormone replacement therapy was halted due to higher rates of breast cancer, heart attack and stroke among women assigned to the drugs to treat menopausal symptoms, a new follow-up study has found those women had no higher risk of death as of 2014 than participants who took a placebo.

Increasing healthcare expenditure due to growing awareness about health related problems. For example, According to OECD, the US spent $10,209 on healthcare per capita, or per person, in 2017. Thats more than any other country in OECDs 36-country consortium, and over $2,000 more than Switzerland, the second-highest spending country. In addition, rising drug development and hormonal imbalance disorders with rising geriatric population are also boosting the hormone replacement therapy market growth. Additionally, the rising womens population between the age group of 45 to 60, which increases the range of menopausal window due to this factor the demand of hormonal replacement therapy, is also growing. However, the hormone replacement therapy has number of side effects which may hamper the market growth. For example, fluid retention, indigestion, headache, and depression, bloating, swelling, nausea, leg cramps. Combined hormone replacement therapy slightly increases the risk of developing breast cancer, womb cancer, ovarian cancer and stroke. For example, Women who take hormone replacement therapy for more than 1 year have a higher risk of breast cancer than women who never use hormone replacement therapy. The risk is linked to all types of hormone replacement therapy except vaginal oestrogen. In spite of that, technological advancements in this field may create the number of opportunities within the forecast period.

North America is expected to dominate the global hormone replacement therapy market due to the increasing awareness about the hormonal replacement therapy And Increasing number of womens which have menopause problems in this region. For example, National Center for Biotechnology Information, in the United States, approximately 1.3 million women become menopausal each year and, 1% of women experience premature menopause before the age of 40. The Asia Pacific is expected to experience surge of demand too, owing to the factors such as increased awareness levels among the end users and improving healthcare infrastructure. Rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy marketin the Europe.

By Product:

By Administration:

By Disease:

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

This comprehensive report will provide:

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Get Full Report: @ https://brandessenceresearch.com/healthcare/hormone-replacement-therapy-market-size

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com

Continued here:
Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current

The many effects of reproductive hormones on the brain – ESHRE

The aim of a well attended Campus meeting organised by the SIG Reproductive Endocrinology in May was to present the latest findings on how sex hormones from various organs influence the brain, not vice versa and to emphasise that theres a psychological as well as physical effect in women.

The first part of the meeting provided a comprehensive update on the basics of how hormones - neuropeptides, AMH and hormonal contraceptives - affect the brain, and may even trigger depression and suicidal thoughts as a result of menstrual cycle syndromes.

Richard Anderson from the University of Edinburgh presented evidence on the key role that the so-called KNDy neurons expressing kisspeptin play in stimulating GnRH and LH, with elevated/fast secretion of these gonadotrophins a feature in PCOS patients. Therapeutic applications based on partial GnRH suppression may become available for PCOS and other conditions using NK3 receptor antagonists, and large clinical trials are under way. NK3 therapies have been associated in trials with a remarkable reduction in menopausal hot flushes, which are linked to GnRH pulses, according to Anderson.

LH over-secretion and reduced fertility characteristics akin to PCOS have also been linked to AMH overexposure, which Joop Laven from Erasmus University in the Netherlands said leads to aberrant wiring of the midbrain. High AMH levels have consequences too for PCOS offspring Laven presented findings showing the hormone impairs aromatase activity in the placenta with LH levels higher in PCOS daughters (and in sons) compared with controls. A possible clinical approach, he suggested, was that PCOS patients delay pregnancy to when embryo yields may be higher and aneuploidy lower.

Inger Sundstrom-Poromaa from Uppsala University Hospital in Sweden cited overwhelming evidence from RCTs for selective serotonin reuptake inhibitors (SSRIs) as a first line therapy for premenstrual dysphoric disorder (PMDD). She also highlighted the pros and cons of other treatments: low dose hormonal contraceptives, GnRH agonists (which alleviate symptoms but have side effects unacceptable to many), progesterone, which Sundstrom-Poromaa concluded is ineffective, and a future novel treatment ulipristal acetate (UA) shown to be effective in curing PMDD symptoms (50% UA group vs 22% placebo) but which cant currently be prescribed following an EMA review.(1)

Despite a 60-year history and widespread worldwide use, the contraceptive pills impact on brain structure via hormone suppression remains underexplored. The 160 Campus participants attending online from 48 countries heard how more (and better designed) longitudinal studies are still needed to establish associations (as suggested in current literature) between the range of progestogens used and brain effects - eg, increased working memory and depression.

During the second half of the meeting, on common fertility-related endocrine conditions, several presenters made lively cases for better treatments. Psychiatrist Vibe Frokjaer from Copenhagen University, Denmark, provided an update on sex hormone fluctuations, mental distress and associations with ART. Research by her and colleagues into women following GnRH agonist and GnRH antagonist protocols for ART suggests that mental distress during treatment is not causally linked to hypogonadism per se or to the choice of protocol.(2) Instead, estrogen sensitivity, brain-based mechanisms and neuroticism appear to play a role, and this needs to be translated into prevention/treatment, she said.

In a presentation on estradiol deficiency, Lawrence Nelson from the Mary Elizabeth Conover Foundation in the US outlined the dramatic consequences of low levels (eg, memory loss and anxiety) and appealed to ESHRE members for wider support of physiologic HRT (with transdermal patches) so women, notably POI patients, get the hormone they were meant to have.(3) Aled Rees, from Cardiff University in Wales, urged clinicians to screen PCOS patients in light of evidence of higher prevalence of emotional distress among these women, and for researchers to adjust for obesity in order to determine its role vs PCOS in psychological symptoms; and an update was given on endometriosis treatments including preliminary findings for publication next year on the role of virtual reality in alleviating chronic pelvic pain.

Campus organiser Cornelis Lambalk said there were many areas still to explore in the field of hormones and the brain, but the ambition is to cover these in a follow-up event next year.

1. Comasco E, Kopp Kallner H, Bixo M, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: A proof-of-concept randomized controlled trial. Am J Psychiatr 2020: 178: 256-265. https://doi.org/10.1176/appi.ajp.2020.200302862. Stenbk D, Toftager M, Hjordt L, et al. Mental distress and personality in women undergoing GnRH agonist versus GnRH antagonist protocols for assisted reproductive technology. Hum Reprod 2015; 30; 103-110. https://doi.org/10.1093/humrep/deu2943. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364; doi:10.1136/bmj.k4810

More here:
The many effects of reproductive hormones on the brain - ESHRE

Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller – The Shotcaller

Market share, size, participants, growth and industry analysis are some of the prominent factors covered in this Hormone Replacement Therapy (HRT) market report. This comprehensive report starts with a goal to give information about market forecast, channel features, end-user market, key pricing structure and different geographies. Besides talking about this, it further mentions key regions, key companies along with their profiles and investment options available in the market. Hormone Replacement Therapy (HRT) market is anticipated to grow hugely during the forecasting period 2021-2027. It further proceeds with geographical analysis covering prominent regions such as North America, Europe, Middle East and Latin America.

Get Sample Copy of Hormone Replacement Therapy (HRT) Market Report at:https://www.globalmarketmonitor.com/request.php?type=1&rid=656651

The study in this report will aid organizations in understanding the major threats and opportunities that retailers face in the global market. In addition, the study offers an all-around view of the competitive landscape as well as a SWOT analysis. This report contains extensive information on product or technological developments in the global Hormone Replacement Therapy (HRT) market, as well as an overview of the effect of these developments on the markets potential growth.To retain their supremacy in the global Hormone Replacement Therapy (HRT) industry, the majority of companies are currently implementing new technology, strategies, product innovations, expansions, and long-term contracts. Following a review of key companies, the report focuses on the startups that are helping to drive business growth. The reports authors identify possible mergers and acquisitions among startups and key organizations in the study. Key Players are working hard to adopt the latest technology to gain a strategic advantage over the competition as new technologies are introduced on a regular basis.

Major Manufacture:Novartis Pfizer Amgen Novo Nordisk Merck & Co. Bayer Eli Lily Wyeth Mylan Laboratories Abbott Laboratories Genentech

Worldwide Hormone Replacement Therapy (HRT) Market by Application:Menopause Hypothyroidism Male Hypogonadism Growth Hormone Deficiency Others

Worldwide Hormone Replacement Therapy (HRT) Market by Type:Oral Parenteral Transdermal Others

Table of Content1 Report Overview1.1 Product Definition and Scope1.2 PEST (Political, Economic, Social and Technological) Analysis of Hormone Replacement Therapy (HRT) Market2 Market Trends and Competitive Landscape3 Segmentation of Hormone Replacement Therapy (HRT) Market by Types4 Segmentation of Hormone Replacement Therapy (HRT) Market by End-Users5 Market Analysis by Major Regions6 Product Commodity of Hormone Replacement Therapy (HRT) Market in Major Countries7 North America Hormone Replacement Therapy (HRT) Landscape Analysis8 Europe Hormone Replacement Therapy (HRT) Landscape Analysis9 Asia Pacific Hormone Replacement Therapy (HRT) Landscape Analysis10 Latin America, Middle East & Africa Hormone Replacement Therapy (HRT) Landscape Analysis 11 Major Players Profile

Ask for a Report Sample at:https://www.globalmarketmonitor.com/request.php?type=3&rid=656651

The study takes into account a broad range of market impact factors, as well as potential emerging factors for different Types, End-Users, Regions and also covers the COVID-19 impact on the market; in order to identify the most promising growth patterns in the global industry. The business ability and demand potential of more than 34 major powers are covered in the research for presenting the most promising investment fields in North America, Europe, Asia Pacific, and Latin America, Middle East, and Africa, offering useful opinions on strategic changes for existing groups and new entrants.

In-depth Hormone Replacement Therapy (HRT) Market Report: Intended AudienceHormone Replacement Therapy (HRT) manufacturersDownstream vendors and end-usersTraders, distributors, and resellers of Hormone Replacement Therapy (HRT)Hormone Replacement Therapy (HRT) industry associations and research organizationsProduct managers, Hormone Replacement Therapy (HRT) industry administrator, C-level executives of the industriesMarket Research and consulting firms

Hormone Replacement Therapy (HRT) Report Provide:Potential opportunities and challenges analysis in Hormone Replacement Therapy (HRT) market.Current and future market outlook in the developed and emerging regional markets.Detailed analysis of the segment that is expected to dominate the market.Regions that are expected to witness the fastest growth during the forecast period.Identify the latest developments, market shares, and strategies employed by the major market players.Comprehensive & in-depth research and after-sales warranty by Global Market Monitor.Analysis of Influences of COVID-19 to the present and future Hormone Replacement Therapy (HRT) market and related industry.

About Global Market MonitorGlobal Market Monitor is a professional modern consulting company, engaged in three major business categories such as market research services, business advisory, technology consulting.We always maintain the win-win spirit, reliable quality and the vision of keeping pace with The Times, to help enterprises achieve revenue growth, cost reduction, and efficiency improvement, and significantly avoid operational risks, to achieve lean growth. Global Market Monitor has provided professional market research, investment consulting, and competitive intelligence services to thousands of organizations, including start-ups, government agencies, banks, research institutes, industry associations, consulting firms, and investment firms.ContactGlobal Market MonitorOne Pierrepont Plaza, 300 Cadman Plaza W, Brooklyn,NY 11201, USAName: Rebecca HallPhone: + 1 (347) 467 7721Email: info@globalmarketmonitor.comWeb Site: https://www.globalmarketmonitor.com

Most Popular Market Research Reports:Body Scrub Market Reporthttps://www.globalmarketmonitor.com/reports/578470-body-scrub-market-report.html

Mobile Projector Market Reporthttps://www.globalmarketmonitor.com/reports/450268-mobile-projector-market-report.html

Bromomethane Market Reporthttps://www.globalmarketmonitor.com/reports/619221-bromomethane-market-report.html

Hair Color Products Market Reporthttps://www.globalmarketmonitor.com/reports/660680-hair-color-products-market-report.html

Viewfinder Market Reporthttps://www.globalmarketmonitor.com/reports/642970-viewfinder-market-report.html

Chewing Gum Base Market Reporthttps://www.globalmarketmonitor.com/reports/440451-chewing-gum-base-market-report.html

Read the original:
Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller

The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier – The Courier

The Male Hypogonadism Market report by Persistence Market Research is focusing on the fact that healthcare providers are into collection of socioeconomic information of the patients, so that tracking at any point of time is possible. This on-the-go monitoring is amongst the ongoing trends in the healthcare industry.

According to Persistence Market Researchs new report,globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceedUS$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact Us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Original post:
The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier

The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Strategizing The Moves For The Next Decade? See Through Sample Of Male Hypogonadism Market Report! https://www.persistencemarketresearch.co/samples/22303

Company Profiles

Starting With The New Decade On A Diligent Note In The Male Hypogonadism Market? https://www.persistencemarketresearch.co/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

How About Obtaining Insights About The Region To Enter Concerning The Male Hypogonadism Market? Press The Purchase Now Button To Have Our Male Hypogonadism Market Report! https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Continue reading here:
The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and…

The latest research report on Hormone Replacement Therapy Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and competitive landscape as well as the key players in the business.

Global Hormone Replacement Therapy Market is valued at USD 19.45 Billion in 2019 and expected to reach USD 33.77 Billion by 2026 with the CAGR of 8.2% overtheforecast period

Get Sample Copy of This Premium Report @ https://brandessenceresearch.com/requestSample/PostId/1402

Hormone replacement therapy is a treatment used to release symptoms of the menopause. The main advantage is that it is a very effective method of controlling menopausal symptoms, and it can make an important difference to a womans quality of life and security. Hormone replacement therapy can also reduce a womans risk of developing osteoporosis and cancer of the colon and rectum. Additionally, hormones are secreted predominantly from the endocrine glands and absorbed into the bloodstream. The hormones that have been most commonly utilised in hormone replacement therapy are progesterone, estrogen, testosterone, adrenal hormones, DHEA, thyroid hormones, pregnenolone, melatonin, and human growth hormone. It is the most effective treatment for menopause symptoms. Systemic hormone replacement therapy helps in treating cancer, rheumatoid arthritis and other diseases. Moreover, this treatment is particularly favorable for patients with growth hormone deficiency, women nearing menopause and elderly people suffering from hypogonadism. It may also protect against osteoporosis.

Global Hormone Replacement Therapy market report is segmented on the basis of product, administration, disease and region & country level. Based upon product, global hormone replacement therapy market is classified into estrogen replacement therapy, human growth hormone replacement therapy, thyroid replacement therapy and testosterone replacement therapy. Based upon administration, the market is divided into oral, parenteral and transdermal. Based upon disease, global hormone replacement therapy market is classified into menopause, hypothyroidism, male hypothyroidism, growth hormone deficiency, cancer and other.

The regions covered in this Hormone Replacement Therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Hormone Replacement Therapy sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Afria, etc.

Request for Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/1402

Big Study Found No Rise in Death Risk among Women who Took Hormone Therapy

September 12th, 2017; after a massive study of hormone replacement therapy was halted due to higher rates of breast cancer, heart attack and stroke among women assigned to the drugs to treat menopausal symptoms, a new follow-up study has found those women had no higher risk of death as of 2014 than participants who took a placebo.

The Growing Awareness about Hormone Replacement is the Key Factor Influencing the Global Hormone Replacement Therapy Market Growth.

Increasing healthcare expenditure due to growing awareness about health related problems. For example, According to OECD, the US spent $10,209 on healthcare per capita, or per person, in 2017. Thats more than any other country in OECDs 36-country consortium, and over $2,000 more than Switzerland, the second-highest spending country. In addition, rising drug development and hormonal imbalance disorders with rising geriatric population are also boosting the hormone replacement therapy market growth. Additionally, the rising womens population between the age group of 45 to 60, which increases the range of menopausal window due to this factor the demand of hormonal replacement therapy, is also growing. However, the hormone replacement therapy has number of side effects which may hamper the market growth. For example, fluid retention, indigestion, headache, and depression, bloating, swelling, nausea, leg cramps. Combined hormone replacement therapy slightly increases the risk of developing breast cancer, womb cancer, ovarian cancer and stroke. For example, Women who take hormone replacement therapy for more than 1 year have a higher risk of breast cancer than women who never use hormone replacement therapy. The risk is linked to all types of hormone replacement therapy except vaginal oestrogen. In spite of that, technological advancements in this field may create the number of opportunities within the forecast period.

North America is expected to Dominate the Global Hormone Replacement Therapy Market

North America is expected to dominate the global hormone replacement therapy market due to the increasing awareness about the hormonal replacement therapy And Increasing number of womens which have menopause problems in this region. For example, National Center for Biotechnology Information, in the United States, approximately 1.3 million women become menopausal each year and, 1% of women experience premature menopause before the age of 40. The Asia Pacific is expected to experience surge of demand too, owing to the factors such as increased awareness levels among the end users and improving healthcare infrastructure. Rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy marketin the Europe.

Key Benefits for Global Hormone Replacement Therapy Market Report-

Complete Report Details @ https://brandessenceresearch.com/healthcare/hormone-replacement-therapy-market-size

Global Hormone Replacement Therapy Market Segmentation:

By Product:

By Administration:

By Disease:

By Regional & Country Analysis:

North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Table of Content

1.1. Research Process

1.2. Primary Research

1.3. Secondary Research

1.4. Market Size Estimates

1.5. Data Triangulation

1.6. Forecast Model

1.7. USPs of Report

1.8. Report Description

2.1. Market Introduction

2.2. Executive Summary

2.3. Global Hormone Replacement Therapy Market Classification

2.4. Market Drivers

2.5. Market Restraints

2.6. Market Opportunity

2.7. Hormone Replacement Therapy Market: Trends

2.8. Porters Five Forces Analysis

2.9. Market Attractiveness Analysis

Continued

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com

Website:https://brandessenceresearch.com/

Originally posted here:
Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and...

Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier – The…

Global Market Monitor recently published a market research report on Hormone Replacement Therapy (HRT), which studied Hormone Replacement Therapy (HRT) industry outlook, competitive situation, regional market analysis, type & application segment analysis, and market trend forecast by 2027.

Get the complete sample, please click:https://www.globalmarketmonitor.com/request.php?type=1&rid=656651

Competition AnalysisMajor enterprises in the global market of Hormone Replacement Therapy (HRT) include:Amgen Novartis Novo Nordisk Wyeth Eli Lily Merck & Co. Abbott Laboratories Mylan Laboratories Bayer Genentech Pfizer

View the Comprehensive Analysis on Various Segment:https://www.globalmarketmonitor.com/reports/656651-hormone-replacement-therapyhrtmarket-report.html

Market Segments by Application:Menopause Hypothyroidism Male Hypogonadism Growth Hormone Deficiency Others

Market Segments by TypeOral Parenteral Transdermal Others

Table of Content1 Report Overview1.1 Product Definition and Scope1.2 PEST (Political, Economic, Social and Technological) Analysis of Hormone Replacement Therapy (HRT) Market2 Market Trends and Competitive Landscape3 Segmentation of Hormone Replacement Therapy (HRT) Market by Types4 Segmentation of Hormone Replacement Therapy (HRT) Market by End-Users5 Market Analysis by Major Regions6 Product Commodity of Hormone Replacement Therapy (HRT) Market in Major Countries7 North America Hormone Replacement Therapy (HRT) Landscape Analysis8 Europe Hormone Replacement Therapy (HRT) Landscape Analysis9 Asia Pacific Hormone Replacement Therapy (HRT) Landscape Analysis10 Latin America, Middle East & Africa Hormone Replacement Therapy (HRT) Landscape Analysis 11 Major Players Profile

Ask for a Report Sample at:https://www.globalmarketmonitor.com/request.php?type=3&rid=656651

Key Regions OverviewMajor countries of North America, Europe, Asia Pacific, and the rest of the world are all exhaustive analyzed in the report. Apart from this, policy mobilization, social dynamics, development trends, and economic development in these countries are also taken into consideration.

In-depth Hormone Replacement Therapy (HRT) Market Report: Intended AudienceHormone Replacement Therapy (HRT) manufacturersDownstream vendors and end-usersTraders, distributors, and resellers of Hormone Replacement Therapy (HRT)Hormone Replacement Therapy (HRT) industry associations and research organizationsProduct managers, Hormone Replacement Therapy (HRT) industry administrator, C-level executives of the industriesMarket Research and consulting firms

Key questions answered in the reportWhat will the market size and growth rate be in 2026?What segment or region will drive or lead market growth and what are the reasons?How will market drivers, constraints and future opportunities affect market dynamics and subsequent analysis of relevant trends?What key strategies are used by top vendors to increase revenue?

About Global Market MonitorGlobal Market Monitor is a professional modern consulting company, engaged in three major business categories such as market research services, business advisory, technology consulting.We always maintain the win-win spirit, reliable quality and the vision of keeping pace with The Times, to help enterprises achieve revenue growth, cost reduction, and efficiency improvement, and significantly avoid operational risks, to achieve lean growth. Global Market Monitor has provided professional market research, investment consulting, and competitive intelligence services to thousands of organizations, including start-ups, government agencies, banks, research institutes, industry associations, consulting firms, and investment firms.ContactGlobal Market MonitorOne Pierrepont Plaza, 300 Cadman Plaza W, Brooklyn,NY 11201, USAName: Rebecca HallPhone: + 1 (347) 467 7721Email: info@globalmarketmonitor.comWeb Site: https://www.globalmarketmonitor.com

Get More Industry Information on Global Market Monitor:Civil Aircraft Weighing Equipment Market Reporthttps://www.globalmarketmonitor.com/reports/580976-civil-aircraft-weighing-equipment-market-report.html

Cargo Aircraft Charter Service Market Reporthttps://www.globalmarketmonitor.com/reports/641569-cargo-aircraft-charter-service-market-report.html

Automotive Driveshaft Market Reporthttps://www.globalmarketmonitor.com/reports/572200-automotive-driveshaft-market-report.html

Radio Frequency Heating Dryers Market Reporthttps://www.globalmarketmonitor.com/reports/657491-radio-frequency-heating-dryers-market-report.html

Ergonomic Gaming Chairs Market Reporthttps://www.globalmarketmonitor.com/reports/456408-ergonomic-gaming-chairs-market-report.html

Natural Sea Sponge Market Reporthttps://www.globalmarketmonitor.com/reports/591978-natural-sea-sponge-market-report.html

Read more:
Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The...

Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr… – UroToday

Testicular cancer is one of the most curable solid malignancies, even in advanced stages. However, the high cure rate among testicular cancer survivors (TCS) is offset by the long-term toxicity of oncologic treatments which include second malignant neoplasms, hypogonadism, pulmonary toxicity, and nephrotoxicity. Compared to the normal population, TCS have an increased risk of dying from circulatory diseases and infections. Such risk is particularly greater in patients who received chemotherapy.1

Elderly people are at high risk of developing cancer and have a decreased ability to control infections. These complications are greatly caused by immunosenescence, the aging process of the immune system. Immunosenescence is characterized by several changes in the lymphocyte subpopulations: there is a decrease in T cells and nave lymphocytes (B and T cells), while CD57+ and CD28- terminally differentiated senescent cells increase. The cell-cycle regulating protein p16INK4a is also a senescence biomarker; its expression in most tissues increases with cellular aging.2

Cytotoxic chemotherapy can induce cellular senescence in normal and cancer cells.3 Therefore, we hypothesized that TCS have premature immunosenescence, which may explain the aforementioned long-term complications. This pilot study aimed to search for lymphocyte senescence surface markers as well as p16INK4a gene expression among TCS who were given chemotherapy.4

Our team conducted a case-control study of TCS matched by age and gender with healthy controls. We included patients with at least threebleomycin, etoposide, and cisplatin (BEP) chemotherapy cycles and no evidence of disease for at least three months. Patients with high-dose chemotherapy were excluded. Peripheral blood mononuclear cells were isolated and lymphocyte subpopulations were analyzed by flow cytometry. B and T cells and their corresponding nave and memory subpopulations were defined according to their surface marker combinations. p16INK4a gene expression in T cells was measured using quantitative polymerase chain reaction.

We found that TCS who had previously received chemotherapeutic agents had statistically significant lower levels of total T cells and CD4+ T cells. Among the CD4+ T lymphocytes, TCS had less nave and increased effector memory cells. Within the CD8+ T lymphocytes, TCS exhibited a decrease in the percentage of nave cells and an increase in CD45RA + CD57+ cells (surface markers related to the later stages of differentiation). Furthermore, we found that there was a statistically significant higher p16INK4a gene expression in TCS as compared to the matched controls. These differences are highlighted in Figure 1.

Figure 1.Immunosenescence profile of testicular cancer survivors (TCS) compared with healthy controls.

Our data suggest that TCS previously treated with chemotherapy may have an immunological phenotype associated with immunosenescence. Potential confounders for these results (like diabetes and hypogonadism) were controlled and excluded. Chemotherapys causal effect, however, remains to be defined. Our study has several limitations, the most important being the cross-sectional nature of it, and we do not know if these alterations persist over time. Future evaluations are necessary to be done in a longitudinal study that allows a patients evaluation at diagnosis, during, and after oncologictreatments.

We believe that further studies are required to help elucidate the clinical implications of the premature immunosenescence in TCS. This is a group of patients that warrants special attention for they receive oncologic treatments at a very young age, and premature immunosenescence may impose many consequences during their lifespan.

Written by: Maria T Bourlon, MD, MSc, Twitter:@BourlonMaite, Francisco J Castro-Alonso, MD, Arturo Carballo, MD, Luis Llorente, MD, Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Mexico City, Mexico

References:

Read more:
Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday

Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News – Jumbo News

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

To remain ahead of your competitors, request for a sample[emailprotected]https://www.persistencemarketresearch.com/samples/29509

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

To receive Methodology request here @https://www.persistencemarketresearch.com/methodology/29509

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

To receive extensive list of important regions, Request Table of content here @https://www.persistencemarketresearch.com/toc/29509

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith

About Us

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping business ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us:

Persistence Market Research (PMR)

Address 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales [emailprotected]

Continued here:
Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News

The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy’s Hockey Law – Murphy’s Hockey Law

According to Persistence Market Researchs new report,globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceedUS$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://murphyshockeylaw.net/

Read more:
The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law

Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha… – UroToday

Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patients with fatigue developed during targeted therapy.

Male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either testosterone undecanoate (1000mg) and targeted therapy or targeted therapy alone. The primary endpoint was the mean change of fatigue from baseline to 28 days according to the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary endpoints were safety, Functional Assessment of Cancer Therapy-Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.

Sixty patients were assigned to receive testosterone and targeted therapy (N=30) or targeted therapy alone (N=30). As of the data cutoff on December 30, 2019, median follow-up was 18.2 months. The study achieved its primary endpoint based on the significant differences at day 28 favoring testosterone over targeted therapy alone regarding the decreased level of fatigue (difference between groups, 22.5 points; 95% confidence interval, 18.4-26.6; P=0.012). Significant changes in scores demonstrating the enhanced quality of life with testosterone compared with targeted therapy were also observed for Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 disease-related symptoms (P=0.01). There were nonsignificant differences in red blood cell count and hemoglobin level between the 2 groups (all P>0.05).

Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.

American journal of clinical oncology. 2021 Jan 27 [Epub ahead of print]

Ilya Tsimafeyeu, Yulia Tishova, Ruslan Zukov, Pavel Borisov, Anastasia Bondarenko, Kristina Zakurdaeva

Kidney Cancer Research Bureau Institute of Oncology, Hadassah Medical Moscow RUDN University I.M. Sechenov First Moscow State Medical University RakFond, Moscow V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk City Clinical Oncology Center, St. Petersburg, Russia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33512910

Originally posted here:
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday

Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX…

RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has appointed Himanshu H. Shah and Shalin Shah as co-CEOs to drive the next phase of growth as the company looks to a potential launch of KYZATREX in Q4 2021 and further the development of Marius deep clinical pipeline.

Himanshu H. Shah brings over 30 years of experience across global capital markets and will continue his role as chairman of the board in addition to co-CEO. He has advised numerous public and private companies over the past decades to help them unlock substantial shareholder value and execute both innovative and pragmatic business strategies.

I am proud to continue serving Marius and work on developing the best treatment options for men with hypogonadism, a common but not widely discussed disease among patients and prescribers, said Himanshu H. Shah, chairman and co-CEO of Marius Pharmaceuticals. Misconceptions about hypogonadism are having a huge impact on the health of millions of men globally and costing the U.S. healthcare system alone billions of dollars annually. There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.

Shalin Shah will also step into the role of co-CEO from chief financial officer and executive vice president of strategy for Marius. Shalin has been integral in driving overall strategy at Marius for the past four years and will oversee the growth of the team and execution of innovative models as it expands both clinically and commercially to become a leading pharmaceutical company.

I am excited for the opportunity to serve Marius in this new capacity, especially at a time when the world is seeing technology and healthcare intersect more than ever, truly helping patients, said Shalin Shah, co-CEO of Marius Pharmaceuticals. I am confident in Marius mission to better the lives of patients by ensuring adequate levels of testosterone and enhance patient care through disruptive technologies and personalization.

Om Dhingra, Ph.D., led the company from initial development of the lead compound through two successful Phase 3 clinical trials and will move into the role of vice chairman. He will help guide the companys clinical development plan and ensure KYZATREX and its differentiating safety and efficacy data is well known in the medical world.

It has been my great pleasure serving the company as CEO. I am very proud of the data we have generated, which we believe will position KYZATREX as the standard of care for patients suffering from hypogonadism globally, said Dr. Om Dhingra, vice chairman of Marius Pharmaceuticals.

If approved by the FDA, KYZATREX has the potential to become the new standard of care for treating patients with hypogonadism. Testosterone is a crucial hormone that is essential to sexual and reproductive health, but also has important functions in metabolic, inflammatory, cardiovascular and neurological health. In the U.S. there are at least six million symptomatic men suffering from hypogonadism, and over 100 million men globally. The resulting medical costs associated with men with untreated hypogonadism and related comorbidities are more than $25 billion in the U.S. alone. Current treatments on the market are dominated by therapies with unappealing administration methods, including auto-injections, in-office infusions and topical gels and creams that have a high transference risk. KYZATREX is an orally administered treatment that avoids the drawbacks that keep men from continuing treatment on available testosterone therapies.

About KYZATREX KYZATREX if approved, will represent a novel oral testosterone replacement therapy option for adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The ReTUNE study was a multi-center, 12-month study across the U.S. that studied the safety and efficacy of KYZATREX in hypogonadal subjects (total testosterone 281 ng/dL). Efficacy was determined by number of subjects in the normal, eugonadal range after 90 days of treatment, including dose titrations, while safety was monitored for a further 9 months while on a steady dose. In addition to testosterone parameters, the study collected Patient Reported Outcomes (PROs), which showed statistically significant results both from baseline and against its comparator. A pivotal six-month Phase 3 study was conducted, in which subjects were monitored using ABPM, now considered the standard BP assessment by the FDA and clinical experts. An improved dose regimen was also used in the pivotal six-month Phase 3 study. The results of the Phase 3 studies will be published in leading medical journals and presented at national conferences in 2021.

The FDA has conditionally accepted KYZATREX as the trade name for this investigational drug. The safety and efficacy have not been fully evaluated by any regulatory authority.

About Marius PharmaceuticalsMarius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency. The companys mission is to improve the functional lives of patients and reduce the risks of the downstream effects of endocrine imbalance by ensuring appropriate level of testosterone. For more information, please visit http://www.mariuspharma.com.

Media Contact: Emily Brice919-610-3319ebrice@fwv-us.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f825d70b-874a-4cef-9160-429f83bbfc66

https://www.globenewswire.com/NewsRoom/AttachmentNg/ba2569ca-0922-4b49-8d68-49424b5e44d4

Himanshu H. Shah

Co-CEO and Chairman of the Board, Marius Pharmaceuticals

Shalin Shah

Co-CEO, Marius Pharmaceuticals

Follow this link:
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX...

Male Hormone Replacement Therapy And The Side Effects – Nerd’s Magazine

Testosterone replacement therapy is done to restore the testosterone levels in men. It is referred to ashormone replacementtherapy. Testosterone is a hormone in men that is produced in the testicles and helps to maintain sex drive, bone density, facial and body hair, sperm production, fat distribution, and red blood cells production. Testosterone levels are highest during adolescence and early stages of adulthood. The levels decline gradually as men age at around 30-40 years.

Testosterone in men may decline due to two reasons. First, it may be due to health conditions that have an effect on the testicles eg cancer, infection, and injury. The disease that results from low levels of testosterone is called hypogonadism. This condition prevents testosterone production by affecting the testicles and pituitary glands. Secondly, it may be as a result of natural decline as a man ages i.e. when men reach 30, they may start experiencing testosterone reduction. Low testosterone levels are considered normal but to some men, it may be extremely abnormal levels hence require replacement.

Decline testosterone levels can lead to symptoms such as reduced sexual desire with few erections that happen spontaneously, physical changes such as decreased muscle strength and mass, increased body fat, swollen and tender breasts, hair loss, fatigue, osteoporosis, emotional changes that lead to reduced motivation and self-esteem eg depression, and infertility. These symptoms can be a result of the side effects of the therapy, thyroid problems, diabetes, and obstructive sleep apnea. Hormone replacement therapy is administered to reverse the lowered testosterone levels in men. The therapy can be recommended to various people with the problem. Both healthy and aging men without hypogonadism diagnosis can be prescribed for testosterone replenishment on showing symptoms. Very high levels of testosterone on the other hand can also cause side effects such as the risk of stroke, infertility, enlarged breasts, and enlarged prostate.

There are several ways in which testosterone replacement can be administered. Testosterone can be taken in gels, intramuscular injections, patches, and topical creams. The method used for administration depends on ones lifestyle and the type of medical need. It can also be taken orally while being monitored to prevent it from being too high. Hormone replacement therapy is meant to induce and maintain secondary characteristics and to correct the symptoms and side effects arising due to low testosterone levels. Testosterone therapy can have some effects when used to prevent normal aging. It worsens sleep obstruction a disorder that causes abrupt stop and start of breathing, promotion of prostate cancer growth, stimulated overproduction of red blood cells increasing blood clotting risks, and reduction in sperm production or testicle shrinkage.

Hypogonadism can be diagnosed as primary or secondary hypogonadism. Abnormalities in testicular levels should be diagnosed, treated, and monitored. Hypogonadism causes testis failure hence reduced production of testosterone concentration and affect the normal number of spermatozoa. It can result from either defect that causes a change in the testis or the hypothalamus. Primary hypogonadism is a result of low T levels, raised gonadotropin levels, or impaired spermatogenesis. Causes of primary hypogonadism include trauma, HIV infection, cancer chemotherapy, myotonic dystrophy, testes exposure to radiation, and infectious orchitis. Secondary hypogonadism is due to low T levels, low or unsuitably normal gonadotropin levels, and spermatogenesis impairment. It is caused by severe obesity, androgenic anabolic steroid withdrawal, hypothalamic tumours, pituitary tumour, and surgery and deprivation therapy of androgen with gonadotropin.

Before testosterone therapy is administered, the clinicians discuss the potential risks and the need for monitoring. Urological evaluation is necessary for men with prostate nodule or induration. In older men, testosterone therapy has a life expectancy of up to 10 years and above. The therapy may lead to side effects and risks such as prostate cancer risk and require prostate monitoring. Some of the symptoms that are evident during T administration include.

Acne and oily skin

Reduced sperm production and fertility

Detection of subclinical cancer

Erythrocytosis

Metastatic prostate cancer growth

Male pattern balding

Breast cancer growth

Obstructive sleep apnea

Heart attack and heart disease

Before settling for testosterone therapy, it is important to take a few cations and think about all the aspects of the therapy. First, analyzing ones health history is key.it is advisable to first consider any other reasons that may be causing the symptoms that are similar to those of low testosterone levels. Sex dysfunctions can also be due to psychological or relationship issues. Cardiovascular disease can also be the reason behind erectile dysfunction. Several clinical measurements may be required to fully diagnose low testosterone levels. The tests are done on varied days and detailed interpretation is needed to establish the amounts of available testosterone. It is also necessary to have information on the possible risks and effects of the therapy and the side effects of the different methods used in administering testosterone.

Baseline evaluation before T administration is done helps to identify and exclude those prone to prostate cancer or who have a high risk of developing prostate cancer. Screening and monitoring in the case of cancer risk require patient and doctor agreement and patient awareness. Factors that should be considered during the baseline assessment are age, race, family history, and prostate examination results. Patient administered with T therapy requires frequent monitoring and assessment to establish whether the therapy is working and in case there are any adverse effects, and that they are responding to the treatment regimen. During the first 12 months of T treatment, it is advisable to get urological consultation to identify ant abnormalities.

Testosterone decline can be due to aging or medical conditions. The treatment and restoration of the levels of testosterone are referred to as testosterone replacement therapy. This therapy requires diagnosis, treatment, and constant monitoring. This is because the therapy treatment has different side effects and risks that vary from one patient to another. A qualified specialist team atLiv Naturalhelps by providing solutions to testosterone deficiency and solve any other health problems that result from low testosterone levels such as erectile dysfunction, low libido, and low muscle mass. Low T levels can only be determined by a diagnosis administered by clinicians i.e. testosterone level test.

(Visited 6 times, 6 visits today)

Go here to read the rest:
Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine

Archives